Ditto Biosciences
United States· Est.
AI‑powered discovery of parasite‑derived autoimmune drugs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered discovery of parasite‑derived autoimmune drugs.
Immunology
Technology Platform
AI‑augmented discovery of parasite‑derived bioactive molecules using protein structure prediction and evolutionary genomics.
Opportunities
Leveraging AI to accelerate natural‑product drug discovery could yield first‑in‑class autoimmune therapeutics and attract strategic pharma partnerships.
Risk Factors
Preclinical status and reliance on emerging AI models create technical and regulatory execution risk.
Competitive Landscape
Few competitors combine parasite biology with AI; differentiation lies in unique natural‑product scaffolds and computational design.